Pharmafile Logo

The role of medical affairs in positive and appropriate engagement with patient advocacy groups

January 30, 2020 |  

Written by Gavin Jones, Dr Alexandra Safronova & Professor Peter Rutherford, OPEN Health

Following a series of workshops at a recent Medical Affairs Professionals Society (MAPS) Congress in Amsterdam, workshop leaders Gavin Jones, Dr Alexandra Safronova and Professor Peter Rutherford share their lessons learnt on how medical affairs departments within pharmaceutical companies can help create better partnerships with patient advocacy groups

Pink divider

Patient advocacy groups continue to mobilise and play an increasingly important role in delivering advice and support helping to get treatments to those most in need by Influencing many elements of drug development and patient access processes. This is very much the case in rare disease where groups give critical support to patients and those close to them through influential programmes delivered  with passion and dogged persistence.

Biopharma recognises the importance of positive engagement and partnership with patient groups. Gaining a far greater understanding of the patient journey helps to translate innovations into actual benefits for patients and caregivers in improved clinical outcomes and patient experience.

A question remains around how, and which part of a biopharma organisation should be involved in building patient group relationships. Many organisations invest in patient advocacy leads to support engagement, but they are often brought in to support dialogue as new treatment is becoming available.  As   patient  groups  are  rightly  getting involved in activities much earlier in the drug development process who should lead engagement at this stage and support over the longer term?

This was a question that was posed at workshops during the recent Medical Affairs Professionals (MAPS) meeting in Europe. MAPS is an organisation that supports the sharing of best practice amongst leaders in this key function of pharmaceutical companies. So, who are medical affairs and what is their role?

Read the full article here: https://bit.ly/37IYg5

Pink divider

Get in touch

For more information on rare disease contact:

Gavin Jones, Director of Rare Disease, OPEN Health

Gavinjones@openhealthgroup.com

This content was provided by OPEN Health

Company Details

 Latest Content from  OPEN Health 

Mapping the clinical and emotional journey to better understand lived experience

Written by OPEN Health's Chris Hodgson, Neil Rees, Sumira Riaz and Karen Petticrew

13th Edition – Spring MEDAFFAIRS Leaders Forum

OPEN VIE (Amanda Pulfer, Strategic Director and Sergio Diaz, Patient Centred Outcomes Consultant) were delighted to speak at the Medical Affairs Leaders Forum yesterday.

Delivering change through better rare disease communications

OPEN Health’s Richard Jones, Gemma Allen and Charlotte Richards discuss how pharma can utilise tools, channels and stakeholders to deliver change and enable better outcomes.

CSR ‘Christmas Spirit’ 2019

OPEN Health champions CSR over Christmas by giving back to the community and increasing our  activities and efforts